Autopsy report · NCT03298009

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“end of contract negociations”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Na
Sponsor: Université de Sherbrooke
Sponsor type: University, hospital or other
Conditions: Type2 Diabetes; Heart Failure
Interventions: Canagliflozin 100mg; Placebo oral capsule; PET imaging
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.